A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

Study Summary

The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.

Conditions

Hepatic Impairment (HI)

Interventions / Drugs

EDG-7500

View on ClinicalTrials.gov ↗

Sponsor

EWTX

Edgewise Therapeutics

Cardiomyopathy

D38/100

Study Details

Enrollment32 participants

Primary Completion—

Lead SponsorEdgewise Therapeutics, Inc.

Data Retrieved2026-04-11 04:13:37.458641+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.